27 results about "Immune reactivity" patented technology

The application discloses a two-dimensional magnetophoresis separation and detection method and system based on weight distribution, and belongs to the field of biochemical analysis. Based on the designed microfluidic chip, the physical property difference between the non-magnetic material and the magnetic material is utilized, the motion difference thereof in the magnetic field is taken as the distinguishing feature, deep-level signal exploration and analysis based on microbead quantification are realized, the number of the compound after the immune reaction and the motion difference in the magnetic field environment are utilized, force analysis calculation and physical field simulation are carried out, different weights are given to the classified signal probes, the signal strength is more accurately revealed, the two-dimensional magnetophoresis analysis method is combined, and the sensitivity and resolution capability of the analysis are effectively enhanced. In addition, the reaction time of the method is short, the operation steps are few, the multiple modes are optional, the scene applicability is strong, and the circulation use can be realized.

The present invention relates to an in vitro method for preparing an immunoreactive agent against human cancer cells infected with an HPV16-associated virus, said method comprising expressing at least part of a nucleic acid sequence encoding an immunoreactive agent obtained from an immune cell stimulated by a complex comprising a human leukocyte antigen (HLA) and a stimulating peptide (stimulating complex), wherein the stimulating peptide (i) consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2, and the HLA is from an HLA supertype HLA-A01; (ii) consists of an amino acid sequence of SEQ ID NO: 11, and the HLA is from an HLA supertype HLA-A02; (iii) consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 34 to SEQ ID NO: 37, and the HLA is from an HLA supertype HLA-A03 / A11; (iv) consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 60 and SEQ ID NO: 61, and the HLA is from an HLA supertype HLA-A24; (v) consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 61, SEQ ID NO: 76 and SEQ ID NO: 77, and the HLA is from an HLA supertype HLA-B07; or (vi) consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 61 and SEQ ID NO: 85 to SEQ ID NO: 92, and the HLA is from an HLA supertype HLA-B15; and wherein HPV16-derived peptides consisting of the same amino acid sequence as the stimulating peptides have been demonstrated to be presented by human HPV16-positive cancer cells, and methods and uses related thereto.

The invention relates to a hybridoma cell strain secreting a rofecoxib monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. According to the invention, a hybridoma cell strain secreting the rofecoxib monoclonal antibody is obtained through screening by preparing a rofecoxib complete antigen and carrying out animal immune reaction and cell fusion steps, the hybridoma cell strain is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.46734. The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity, the IC50 value to rofecoxib is 20.0 ng / mL, the cross reaction rate to various rofecoxib functional analogues is smaller than 1%, the monoclonal antibody can be applied to preparation of rofecoxib detection products, and an efficient detection method and means are provided for detection of rofecoxib residues in food.

The invention provides a linear epitope of an African swine fever virus CP312R protein. The amino acid sequence of the linear epitope is SEQ ID NO: 1 or SEQ ID NO: 2. The antigen epitope polypeptide provided by the invention has good antigen specificity and immunoreactivity. The polypeptide can be efficiently combined with an African swine fever virus specific antibody, background interference is low, cross reaction is small, and detection sensitivity and accuracy are remarkably improved. By using the polypeptide as a coating antigen in immunodetection methods such as ELISA or colloidal gold immunochromatography, rapid and accurate detection of ASFV infection can be realized, and the detection result is stable and reliable. Compared with a traditional whole virus antigen or a crude extract antigen, the epitope polypeptide has the advantages of being simple and convenient to prepare, small in batch difference, high in safety and the like, and is suitable for ASFV serological monitoring and diagnosis application.

The present invention relates to a methionine sulfoxide reductase B1 inhibitor and an anticancer composition comprising same. More specifically, the present invention relates to 4-[3-(4-ethylphenyl)-5-(4-hydroxyphenyl) -4,5-dihydro -1 H-pyrazol-1-yl]benzene-1-sulfonamide or 6-chloro-10-(4-ethylphenyl)-4-hydroxypyrimido[4,5-b]quinolin-2(10H)-one, which is a MsrB1 inhibitor, and an anticancer composition comprising same. The MsrB1 inhibitor of the present invention has been confirmed to inhibit differentiation into tumor-friendly M2 macrophages and to suppress tumor growth. In addition, the MsrB1 inhibitor of the present invention was found to exhibit anticancer effects through immune regulation within the tumor microenvironment, and thus can be usefully applied as a composition for cancer treatment.

The present application relates to the field of image recognition, and more particularly to a method and system for predicting and analyzing adrenal metastasis based on image recognition. The method comprises the following steps: collecting patient adrenal PET-CT monitoring images at multiple time points, and performing visual detection of metastasis at each time point, and extracting metastasis bounding boxes at multiple time points; according to the metastasis bounding box, the dynamic fluctuation analysis of the surrounding tissue microenvironment and the boundary immune influence degree evaluation are carried out, and a multi-cycle immune response intensity graph is constructed; the metastasis change trend evolution of the metastasis bounding box is carried out, and the metastasis image change trend graph at different time points is obtained; according to the metastasis bounding box, the surrounding tissue texture feature difference is identified, and the potential tumor metastatic cells are extracted. The present application predicts the future change of metastasis by dynamically predicting the development trend of adrenal metastasis, and provides more intuitive metastasis change at different time points.

The invention relates to an application of an RIPK2 inhibitor GSK2983559 in preparation of a medicine for preventing, treating and / or relieving smoke inhalation type lung injury, and the application focuses on targeted inhibition of a core inflammation signal channel of RIPK2-NF-kappa B, regulation and control of excessive activated natural immune response after smoke inhalation, alleviation of acute inflammation injury of airways and pulmonary alveoli, treatment of the smoke inhalation type lung injury, treatment of the smoke inhalation type lung injury, treatment of the smoke inhalation type lung injury, treatment of the smoke inhalation type lung injury and / or treatment of the smoke inhalation type lung injury. And a novel targeted therapeutic drug is provided for clinically preventing and treating lung injury caused by smoke inhalation.

The present invention relates to the field of feature extraction technology, specifically to a feature extraction method and system for CAR-NK cell data, comprising the following steps: collecting CAR-NK cell samples, performing protein analysis on the CAR-NK cell samples in batches, recording changes in protein expression in each batch of CAR-NK cell samples, and performing quantitative analysis on metabolite samples to obtain metabolite concentration data, and standardizing the concentration data to obtain basic data of the cell samples. In the present invention, by quantitatively analyzing proteins and metabolites in CAR-NK cell samples, the response characteristics of cells under different immune environments can be fully captured, immune response grouping and cluster analysis clarify the impact of the immune environment on cell function, the protein-metabolite interaction network reveals the interaction between molecules inside and outside the cell, and by screening and verifying immune markers, provides an accurate basis for immune function assessment. The quantitative analysis of immune reactivity characteristics can track the immune response process in real time, thereby improving the accuracy and depth of research.

A conjugate obtained by binding a benzodiazepine to an antibody or an antigen-binding fragment thereof having immunological reactivity with MCEMP1 protein, the conjugate being an antibody-drug complex (ADC) having a strong anti-tumor effect and being useful for the treatment and / or prevention of cancer, particularly cancer expressing MCEMP1 protein on the cell surface.

The invention provides an immune detection method of an immune checkpoint detection kit, and belongs to the technical field of immune checkpoint detection kits.The immune detection method comprises the steps that an immune reaction system containing immune checkpoint antibodies is prepared, incubation is conducted under the constant temperature condition to form a sandwich type immune complex, and the sandwich type immune complex is obtained; phycoerythrin labeled streptavidin is added for fluorescence labeling, a flow cytometer is adopted for fluorescence signal detection after interference substances are removed through multiple times of cleaning, fluorescence image data are processed through an image partitioning optimization model, image processing parameters are dynamically adjusted through a signal enhancement algorithm function and a gating weight function, and the fluorescence image is obtained. A multi-scale feature extraction network based on a visual converter architecture is adopted to realize accurate processing of a complex fluorescence image, finally correlation analysis and matrix decomposition calculation are performed on fluorescence intensity data, and a detection analysis model is established to output index concentration values of immune checkpoints. The problem that complex fluorescence image data are difficult to process accurately at present is solved.

Provided herein are methods for activating an immune cell in a subject. In some embodiments, the methods comprise passing an immune cell from a subject through an immune modulating chamber comprising a tumor cell, thereby activating the immune cell, and returning the activated immune cell to the subject. In some embodiments, the methods further comprise isolating an immune cell-containing portion of a sample and passing the immune cell-containing portion through the immune modulating chamber. Methods of treating cancer and methods of inducing an immune response against a tumor are also provided herein.

The invention belongs to the technical field of chemistry and medicine, and relates to a natural killer T cell agonist which contains a sulfonamide group or a part of the sulfonamide group and has immunoregulatory activity and application of the natural killer T cell agonist. The agonist is a compound with a structure as shown in a formula (1) or a pharmaceutically acceptable salt thereof. According to the invention, a sulfonamide group is introduced to an acyl chain of alpha GalCer, and the binding force between glycolipid molecules and CD1d is enhanced by forming an additional hydrogen bond. By adopting the design concept, the NKT cell agonist with better immunomodulatory activity is obtained, the synthesis method of the series of compounds is simple and efficient, and the screened novel alpha GalCer analogue has obviously improved immunostimulatory activity compared with the original alpha GalCer, can induce immunoreactions with different biases, and has good immunomodulatory activity. Potential candidate drugs are provided for immunotherapy and immune modulation. # imgabs0 #

The present invention relates to a medicament for treatment and / or prevention of cancer, comprising an antibody or a fragment thereof having an immunological reactivity with CAPRIN-1 protein, and an inhibitor of synthesis of N-glycoside-linked sugar chain of a glycoprotein together or separately in combination.

Provided herein are methods for stimulating an immune response to a target cell population or a target tissue in a subject by administering to the subject a composition comprising an amphiphilic ligand conjugate. Such an amphiphilic ligand conjugate can comprise a lipid, one or more cargos (e.g., a CAR ligand, a chimeric cytokine receptor target, a chimeric co-stimulation receptor target, a synNotch receptor target), and optionally a linker.

The present disclosure pertains to multispecific antibodies or antigen-binding fragments thereof, and methods of using such multispecific antibodies or antigen-binding fragments thereof. In some embodiments, the present disclosure provides multispecific antibodies or antigen-binding fragments thereof comprising: (i) a first antigen-binding domain that selectively binds to B7-H7, and (ii) a second antigen-binding domain that selectively binds an immune effector cell antigen. Such multispecific antibodies or antigen- binding fragments thereof disclosed herein can be used in methods of treating a subject having a disease, disorder, or condition and / or modulating an immune response in a subject.

An antibody or antigen-binding fragment thereof having immunological reactivity with the MCEMP1 protein can be used as an active ingredient of a pharmaceutical composition for treating and / or preventing a disease in which mast cells expressing the MCEMP1 protein on the cell surfaces exacerbate the pathologic condition.

The present invention provides a novel CAR design containing a modified CD3ζ chain, and cells containing genetically modified immune-responsive cells (e.g., T cells, NK cells, or CTL cells) containing the CAR. [Solution] This disclosure provides a chimeric antigen receptor (CAR) that binds to an antigen of interest. The CAR can bind to a tumor antigen or a pathogen antigen. In certain non-limiting embodiments, the CAR comprises an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide.

Provided herein is a cell macroencapsulation device composed of hydrogel in a 3D conformation that optimizes encapsulated cell viability and function when transplanted into a vascularized tissue space. The hydrogel macroencapsulation device is intended to reduce or eliminate immune response to the cell graft, while allowing exchange of encapsulated cell-secreted products, such as insulin. Also described herein is an injection-mold and fabrication process to generate the hydrogel macroencapsulation devices for use in the clinic.

An immunoresponsive cell, such as a T-cell expressing(i) a second generation chimeric antigen receptor comprising:(a) a signalling region;(b) a co-stimulatory signalling region;(c) a transmembrane domain; and(d) a binding element that specifically interacts with a first epitope on a target antigen; and(ii) a chimeric costimulatory receptor comprising(e) a co-stimulatory signalling region which is different to that of (b);(f) a transmembrane domain; andg) a binding element that specifically interacts with a second epitope on a target antigen.This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.

This disclosure provides methods of increasing in vivo transfection efficiency and pharmacologic activity of T cells, by administering multiple small doses within a compact time period of T cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor that recognizes an antigen of a cell against which immune activity is to be directed. Also provided are methods of depleting B cells, and methods of treating B cell-mediated diseases and disorders by depleting B cells and achieving immunological reset, entailing administration of immune cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor recognizing a B cell marker as multiple small doses within a compact time period. The antigen receptor can be a T cell receptor or a chimeric antigen receptor.

The invention belongs to the technical field of gene engineering, and discloses a leaf blight pathogen effect protein GcNpp1 as well as a coding gene and application thereof, the amino acid sequence of the leaf blight pathogen effect protein GcNpp1 is shown as SEQ ID NO.2, and the nucleotide sequence of the coding gene of the leaf blight pathogen effect protein GcNpp1 is shown as SEQ ID NO.1. The invention further discloses a preparation method of the leaf blight pathogen effect protein GcNpp1. The leaf blight pathogen effect protein GcNpp1, the coding gene of the leaf blight pathogen effect protein GcNpp1 or the biological material can be applied to improvement of disease resistance of plants to pathogenic bacteria and induction of plant immune response and plant cell necrosis. The effect protein can also be used as an active component for preparing a biological preparation for improving plant disease resistance. The coding gene of the blight pathogen effect protein GcNPP1 negatively regulates the infection process of pathogenic bacteria by secreting the effect protein, also serves as an immune elicitor to induce plant system resistance, can be applied to improvement of plant disease resistance, and provides a new direction for plant disease control.

Providing a fusosome composition for T cell delivery. [Solution] This disclosure provides, at least in part, methods and compositions for in vivo fusosome delivery. In some embodiments, the fusosome comprises a combination of elements that promote specificity to target cells, e.g., one or more fusogens, a positive target cell-specific regulatory element, and a non-target cell-specific regulatory element. In some embodiments, the fusosome composition comprises one or more modifications that reduce the immune response to the fusosome.

The present invention relates to a pharmaceutical composition for treatment and / or prevention of cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 or more consecutive amino acids.

An immunoresponsive cell, such as a T-cell expressinga second generation chimeric antigen receptor comprising:(a) a signalling region;(b) a co-stimulatory signalling region;(c) a transmembrane domain; and(d) a binding element that specifically interacts with a first epitope on a target antigen; anda chimeric costimulatory receptor comprising(e) a co-stimulatory signalling region which is different to that of (b);(f) a transmembrane domain; andg) a binding element that specifically interacts with a second epitope on a target antigen.This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.

The invention discloses a magnetic bead-bicolor quantum dot premixed host-guest encoding microsphere, a preparation method thereof and a multivariate analysis kit, bicolor hydrophobic quantum dots are premixed and assembled into dendritic silicon dioxide dSiO2, and the color proportion is regulated and controlled through premixing to prepare an encoding guest sphere. The main sphere is a 5-micron polystyrene sphere filled with superparamagnetic particles, a large number of object spheres are coupled to the surface of the main sphere through a statistical averaging effect, the fluctuation (standard deviation) of an integrally output coding signal (blue / red intensity ratio) is small, and the uniformity of the coding signal is improved. Meanwhile, small-size hollow silicon dioxide nanotubes are used for loading green quantum dots, so that the immunoreaction kinetics of the detection probe is improved. A core-satellite structure immune complex is formed by full quantum dot narrow emission under unitary excitation (405nm), blue-red double colors are used as coding colors, green is used as signal colors, coding multivariate analysis is carried out, and high-sensitivity and high-accuracy imaging quantitative analysis can be realized on various respiratory tract pathogen antigens.

The present disclosure relates to the fields of adoptive cell therapy and treatments for autoimmune diseases and disorders. The present disclosure provides engineered cells, compositions, and methods for treating patients suffering from autoimmune disorders and which are poorly treated by other methods. Specifically, the engineered cells, compositions, and methods selectivity destroy cells that mediate autoimmunity, both B and T cells, yet spare cells that modulate the autoimmune inflammatory response, e.g., regulatory T cells, or are not otherwise involved in the autoimmune response. Finally, the engineered cells are designed to avoid fratricide during their manufacturing.

An object of the present invention is to identify cancer antigen proteins specifically expressed on the surface of cancer cells and to provide a use of antibodies targeting such proteins as therapeutic and / or preventive agents for cancer. The present invention relates to, for example, a pharmaceutical composition for treatment and / or prevention of a cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with an MCEMP1 protein having an amino acid sequence shown in any one of the even numbered SEQ ID NOS: 2 to 8 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence, or with a fragment of the MCEMP1 protein comprising 7 or more consecutive amino acids.